



**HAL**  
open science

## **Morphine withdrawal recruits lateral habenula cytokine signaling to reduce synaptic excitation and sociability**

Kristina Valentinova, Anna Tchenio, Massimo Trusel, Joseph Clerke, Arnaud Lalive, Stamatina Tzanoulinou, Alessandro Matera, Imane Moutkine, Luc Maroteaux, Rosa Paolicelli, et al.

### ► To cite this version:

Kristina Valentinova, Anna Tchenio, Massimo Trusel, Joseph Clerke, Arnaud Lalive, et al.. Morphine withdrawal recruits lateral habenula cytokine signaling to reduce synaptic excitation and sociability. Nature Neuroscience, 2019, 22 (7), pp.1053-1056. 10.1038/s41593-019-0421-4 . hal-02348080

**HAL Id: hal-02348080**

**<https://hal.science/hal-02348080>**

Submitted on 12 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Morphine withdrawal recruits habenular cytokine signaling to reduce**  
2 **synaptic excitation and sociability**

3

4 Kristina Valentinova<sup>1,4,6</sup>, Anna Tchenio<sup>1,6</sup>, Massimo Trusel<sup>1</sup>, Joseph A.  
5 Clerke<sup>1</sup>, Arnaud L. Lalive<sup>1</sup>, Stamatina Tzanoulidou<sup>3</sup>, Alessandro Matera<sup>5</sup>,  
6 Imane Moutkine<sup>2</sup>, Luc Maroteaux<sup>2</sup>, Rosa C. Paolicelli<sup>5</sup>, Andrea Volterra<sup>1</sup>,  
7 Camilla Bellone<sup>3</sup> and Manuel Mameli<sup>1,2\*</sup>

8

9 <sup>1</sup> The Department of Fundamental Neuroscience, The University of Lausanne  
10 1005 Lausanne, Switzerland.

11 <sup>2</sup> Inserm, UMR-S 839, 75005 Paris, France.

12 <sup>3</sup> Department of Basic Neuroscience, The University of Geneva, Switzerland.

13 <sup>4</sup> Department of Physiology, The University of Bern, Bern, Switzerland.

14 <sup>5</sup> Department of Physiology, The University of Lausanne 1005 Lausanne,  
15 Switzerland.

16 <sup>6</sup>These authors equally contributed to the work.

17

18

19 To whom correspondence should be addressed:

20 Manuel Mameli, PhD

21 ORCID ID: 0000-0002-0570-6964

22 The Department of Fundamental Neuroscience, The University of Lausanne  
23 1005 Lausanne, Switzerland.

24 Email [manuel.mameli@unil.ch](mailto:manuel.mameli@unil.ch)

25

26

27

28

29

30

31

32

33

34

35 **Abstract**

36 **Opiate withdrawal promotes a wealth of negative emotional states**  
37 **including low sociability. The lateral habenula (LHb) encodes aversive**  
38 **stimuli and contributes to negative symptoms of drug withdrawal.**  
39 **However, whether adaptations at precise habenular circuits are**  
40 **instrumental for the opiate withdrawal state remains unknown. We**  
41 **report that, in mice, morphine withdrawal (MORwd) diminishes**  
42 **glutamatergic transmission onto raphe-projecting lateral habenula (LHb)**  
43 **neurons. This MORwd-driven synaptic plasticity occurs along with**  
44 **microglia adaptations and increased cytokine levels. Specifically, it**  
45 **requires TNF $\alpha$  release and subsequent activation of neuronal TNF-**  
46 **Receptor-1, to ultimately gate sociability deficits. Hence, drug-driven**  
47 **modulation of cytokines controls synaptic efficacy and opiate**  
48 **withdrawal-evoked behavioral adaptations.**

49

50 **Introduction**

51 Opiate withdrawal produces negative emotional states including low mood  
52 and reduced sociability, contributing to relapse during drug abstinence<sup>1,2</sup>.  
53 Dysfunction of the lateral habenula (LHb) – a nucleus controlling  
54 monoaminergic systems and processing aversive stimuli – underlies  
55 depressive symptoms typical of mood disorders and drug withdrawal<sup>3</sup>.  
56 Opiates also affect LHb function<sup>4,5</sup>. However whether morphine withdrawal  
57 reorganizes LHb circuits to underlie specific aspects of the withdrawal state  
58 remains unknown.  
59 Using mice, we found that morphine withdrawal emerging after naloxone  
60 precipitation or a prolonged abstinence period i. reduces glutamatergic  
61 transmission onto LHb neurons projecting to the raphe nucleus and ii.  
62 remodels microglia and cytokine signaling. Finally, the withdrawal-driven  
63 cytokine adaptations are instrumental for the diminished synaptic strength and  
64 opiate-withdrawal sociability deficits.

65

66

67 **Results**

68 **Morphine withdrawal-driven synaptic plasticity in the LHb**

69 We subjected mice to naloxone-precipitated MORwd to examine its  
70 repercussions on glutamatergic synapses onto LHb neurons<sup>1</sup>. Indeed,  
71 aberrant LHb excitatory transmission underlies negative symptoms in rodent  
72 models of depression and addiction<sup>3</sup>. Spontaneous excitatory postsynaptic  
73 current (sEPSC) amplitudes, but not frequencies, were reduced only in LHb  
74 neurons located in the medial aspect (<sup>Med</sup>LHb; lateral LHb, <sup>Lat</sup>LHb;  
75 Supplementary Fig. 1a and 1b). Accordingly, MORwd diminished  
76 AMPAR:NMDAR ratios solely in the medial territory (Fig. 1a and  
77 Supplementary Fig. 1c) without affecting neurotransmitter release assessed  
78 by trains of synaptic stimulation (Supplementary Fig. 1d). **Recordings**  
79 **obtained 1 hour after the last MOR injection (without naloxone) yielded saline-**  
80 **comparable AMPAR:NMDAR ratios (Fig. 1b). In contrast, spontaneous**  
81 **MORwd persistently decreased AMPAR:NMDAR ratios in the <sup>Med</sup>LHb up to 30**  
82 **days after the last MOR injection (Fig. 1b).**

83 To assess whether MORwd affects AMPAR conductance or number, we used  
84 peak-scaled non-stationary fluctuation analysis of <sup>Med</sup>LHb-recorded sEPSCs<sup>6</sup>.  
85 While estimated single-channel conductance remained unaffected in MORwd  
86 slices, the number of channels opened at the peak positively correlated with  
87 amplitude values (Supplementary Fig. 1e). MORwd failed to alter AMPAR-  
88 EPSC rectification properties (Supplementary Fig. 1f), whereas it reduced  
89 glutamate uncaging-evoked AMPAR:NMDAR ratios, yielding a decrease only  
90 in absolute AMPAR currents (Supplementary Fig. 1g). Altogether, this  
91 suggests that MORwd reduces, in a territory-specific fashion, the number of  
92 AMPARs without affecting their biophysical properties, NMDARs or  
93 presynaptic glutamate release.

94 MORwd-evoked glutamatergic plasticity occurs onto <sup>Med</sup>LHb neurons, which  
95 innervate downstream structures including the raphe nucleus and the ventral  
96 tegmental area (VTA)<sup>7</sup>. We therefore examined the strength of glutamatergic  
97 synapses onto retrobeads-labeled Raphe- and VTA-projecting LHb neurons  
98 (LHb<sub>Raphe</sub> and LHb<sub>VTA</sub> respectively). MORwd diminished AMPAR:NMDAR

99 ratios solely in LHB<sub>Raphe</sub> neurons (Fig. 1c, d) suggesting that MORwd plasticity  
100 is specific for discrete habenular circuits.

101

## 102 **Cytokine signaling in the LHB interfaces morphine withdrawal plasticity**

103 Which induction mechanism gates MORwd-driven plasticity onto <sup>Med</sup>LHB  
104 neurons? Inflammatory responses and glial cell activation emerge during  
105 opioid withdrawal<sup>8,9</sup>. Indeed, spontaneous morphine withdrawal drives  
106 adaptations in microglia and pro-inflammatory cytokine release (i.e. tumor  
107 necrosis factor- $\alpha$  (TNF $\alpha$ ))<sup>10</sup>. Notably, cocaine also leads to reduced microglia  
108 arborization along with TNF $\alpha$ -dependent AMPAR internalization, partly  
109 underlying drug-mediated behavioral adaptations<sup>9,11</sup>. **We thereby examined**  
110 **microglia morphology and cytokine levels during MORwd. We found that,**  
111 **within the <sup>Med</sup>LHB, MORwd i. reduced microglial markers including Iba1 and**  
112 **CD68 and ii. diminished microglial cell volume (Fig. 2a–d).** In parallel,  
113 naloxone- and spontaneous MORwd increased TNF $\alpha$  immunolabeling within  
114 the LHB (Fig. 2e and Supplementary Fig. 2a–d). Altogether, these findings  
115 support the engagement of inflammatory responses and cytokine signaling  
116 within the LHB during MORwd.

117

118 We then reasoned that if MORwd promotes TNF $\alpha$  release, artificially  
119 increasing its levels should prove sufficient to recapitulate MORwd-driven  
120 synaptic plasticity. **Accordingly, incubating LHB-containing slices from saline-**  
121 **injected mice with exogenous TNF $\alpha$  reduced AMPAR:NMDAR ratios in the**  
122 **<sup>Med</sup>LHB. This effect was absent in <sup>Lat</sup>LHB, and occluded by naloxone-**  
123 **precipitated as well as spontaneous MORwd (Fig. 3a–b and Supplementary**  
124 **Fig. 3a).** TNF $\alpha$  release may arise from microglial Toll-Like Receptor 4 (TLR-4)  
125 signaling<sup>12</sup>. Systemically activating TLR-4 with the agonist MPLA in MOR-  
126 treated mice, instead of naloxone, mimicked MORwd plasticity (Fig. 3c).  
127 Moreover, MPLA application in acute slices from MOR-treated animals  
128 reduced AMPAR currents in <sup>Med</sup>LHB, but not in <sup>Lat</sup>LHB (Fig. 3d and  
129 Supplementary Fig. 3b). **This MPLA-driven reduction in EPSCs did not occur**  
130 **in the presence of a dominant negative peptide, which blocks the soluble form**  
131 **of TNF $\alpha$  (XENP1595; Supplementary Fig. 3c)<sup>9</sup>.** Furthermore, MORwd

132 occluded MPLA-driven synaptic depression (Fig. 3d) and systemic injection of  
133 the dominant negative peptide XENP1595 prevented MORwd-induced  
134 plasticity (Supplementary Fig. 3d). Altogether, this supports *i.* TLR-4  
135 expression within the LHb (See Allen Brain Atlas), *ii.* its effect on AMPARs via  
136 TNF $\alpha$  signaling, and *iii.* the necessity and sufficiency of TNF $\alpha$  for MORwd-  
137 driven reduction of LHb glutamatergic transmission.

138

### 139 **Requirement of TNF-R1 for morphine withdrawal synaptic and** 140 **behavioral adaptations**

141 TNF $\alpha$  triggers its central effects partly through TNF receptor-type-1 (TNF-  
142 R1)<sup>13</sup>. To test whether this applies to MORwd-driven plasticity in the LHb, we  
143 employed TNF-R1<sup>fl/fl</sup> mice to Cre-dependently knock-down TNF-R1  
144 expression in LHb neurons (Fig. 4a–c). After viral injection, AAV<sub>Cre</sub>-TNF-R1<sup>fl/fl</sup>  
145 mice failed to show MORwd-driven AMPAR:NMDAR ratio reduction compared  
146 to AAV<sub>Control</sub>-infused mice (Fig. 4d). This highlights the necessity of neuronal  
147 TNF-R1 for MORwd-driven depression of synaptic AMPARs in LHb.

148

149 MORwd drives negative emotional symptoms among which social  
150 detachment<sup>1</sup>. Similarly, LHb dysfunction contributes to the negative  
151 behavioural states emerging in mood disorders and addiction, although its  
152 implications for sociability remains poorly addressed<sup>14,15,16</sup>. Hence, we  
153 examined the contribution of the LHb-to-Raphe pathway, the locus of MORwd  
154 plasticity, for social behavior. We employed an intersectional chemogenetic  
155 viral approach to reduce the efficiency of the LHb-to-Raphe projection. This  
156 combined the retrograde expression of cre-recombinase (HSV-Cre in dorsal  
157 raphe) with cre-dependent expression of hM4Di (rAAV-hM4Di-mCherry,  
158 DREADDi, in LHb; Fig. Supplementary 4a). Reducing LHb-to-Raphe  
159 efficiency with clozapine-N-oxide diminished social preference (Fig.  
160 Supplementary 4b), supporting LHb contribution to social behaviors.  
161 Next, we recapitulated MORwd-driven reduction in social preference in  
162 C57Bl6 mice (Fig. 4e and Supplementary Fig. 4c–f)<sup>1</sup>. We then prepared slices  
163 from MORwd mice showing low or high sociability scores, and found that  
164 AMPAR:NMDAR ratios, recorded in <sup>Med</sup>LHb, positively correlated with the

165 social score (Fig. 4f). This indicates that reduced synaptic strength in the LHb  
166 predicts opiate-WD-driven sociability deficits.

167

168 Notably, microglia and TNF $\alpha$  signaling also contributes to social behaviors<sup>17–</sup>  
169 <sup>19</sup>. We thereby predicted that LHb TNF-R1 ablation, not only prevents MORwd  
170 synaptic plasticity (Fig. 4d), but also MORwd low sociability. Indeed, MORwd-  
171 driven sociability deficits were absent after cre-dependent LHb TNF-R1  
172 knock-down (Fig. 4g and Supplementary Fig. 4g–k). This genetic intervention  
173 did not affect locomotion (Supplementary Fig. 3l).

174

## 175 Discussion

176 We found that MORwd-driven TNF $\alpha$  release requires neuronal TNF-R1 to  
177 reduce AMPAR transmission onto raphe-projecting, medially-located, LHb  
178 neurons. This ultimately gates MORwd-driven social impairment, a negative  
179 symptom typical of opiate withdrawal.

180

181 The TNF $\alpha$ -TNF-R1 engagement within the LHb represents a previously  
182 unidentified mechanism underlying precise cellular and behavioural aspects of  
183 MORwd. Yet this is consistent with the following: *i.* drugs and drug-  
184 withdrawal-mediated modulation of AMPAR transmission partly rely on  
185 cytokine signaling<sup>9</sup>; *ii.* inhibition of TLR-4 attenuates MORwd symptoms<sup>20</sup>; *iii.*  
186 TNF-Rs contribute to social behaviors<sup>18</sup>. **Notably, in pyramidal neurons of the**  
187 **hippocampus and cortex, TNF $\alpha$  regulates AMPAR exocytosis and their**  
188 **surface expression<sup>21,22</sup>. This phenomenon is opposite at striatal synapses**  
189 **where, similarly to the LHb, TNF $\alpha$  application results in decreased AMPAR**  
190 **transmission<sup>9,23</sup>. This divergence may arise from different TNF $\alpha$  release**  
191 **dynamics, TNF receptors expression and signaling, or alternatively the**  
192 **properties of AMPAR anchoring at postsynaptic compartments within the LHb.**  
193 **MORwd modifies the morphology of microglia in the LHb. This is, at least**  
194 **partly, consistent with previous findings<sup>9</sup>, yet it remains correlative with**  
195 **respect to TNF $\alpha$  levels. This heightens the need to fill the gap in**  
196 **understanding microglia function and its relationship with TNF $\alpha$  within the**  
197 **habenular complex. Overall, while pharmacotherapies targeting pro-**

198 inflammatory pathways in substance abuse are missing, our data further  
199 support cytokine signaling as a cellular pillar for aspects of drug addiction and  
200 more largely of psychiatric disorders<sup>9,24</sup>.

201

202 MORwd-driven TNF $\alpha$ -dependent depression of AMPAR transmission occurs  
203 at LHB<sub>Raphe</sub> neurons. From a circuit standpoint, this may provide an ‘anti-  
204 social’ signal<sup>25</sup> likely through reduced actions onto raphe neuronal  
205 populations. This is consistent with the evidence reported here that  
206 chemogenetic manipulation of the LHB-to-Raphe projection diminishes  
207 sociability. Alongside, dopamine- and serotonin-containing neurons in the  
208 raphe contribute to social behaviors, and medially-located LHB neurons  
209 monosynaptically connect to the latter<sup>26–29</sup>. Understanding the repercussions  
210 of LHB activity onto raphe neuronal subtypes during MORwd remains an  
211 important aspect for future investigation.

212

213 In conclusion, our data support the participation of cytokine-mediated  
214 plasticity for opiate-evoked negative symptoms, a mechanism by which LHB  
215 ultimately contributes to the addiction spiral.

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230



231 **Figure legends**

232 **Figure 1 MORwd-driven projection-specific synaptic depression in LHb.**

233 (a) Naloxone-precipitated MORwd (NP-MORwd) effect on AMPAR:NMDAR  
234 ratios from <sup>Lat</sup>LHb ( $n_{\text{mice/cells}}=7-8/11$ ; saline (gray) versus NP-MORwd (orange):  
235  $t_{20}=0.0548$ ,  $P=0.957$ ) and <sup>Med</sup>LHb: ( $n_{\text{mice/cells}}=7-8/12-13$ ; saline (black) versus  
236 NP-MORwd (red):  $t_{23}=2.210$ ,  $*P=0.037$ ) (b) Left: schematic of spontaneous  
237 withdrawal timeline. Right: AMPAR:NMDAR ratios recorded from <sup>Med</sup>LHb 1  
238 hour, 10, 20 or 30 days after saline or MOR treatment ( $n_{\text{mice/cells}}=3-6/11-22$ ,  
239 saline 1 hour and 10 days after last injection pooled (black) versus MOR  
240 withdrawal 1 hour (open red) and MOR 10, 20 and 30 days withdrawal (red),  
241  $F_{(4, 62)}= 3.90$  one-way ANOVA,  $**P=0.007$ ). (c) Retrobeads in Raphe (left) and  
242 retrogradely-labeled LHb<sub>Raphe</sub> neurons (right) images. AMPAR:NMDAR ratios  
243 from LHb<sub>Raphe</sub> neurons ( $n_{\text{mice/cells}}=5/10-11$ , saline (black) versus NP-MORwd  
244 (red),  $t_{19}=3.153$ ,  $**P=0.005$ ). (d) Same as c but in VTA ( $n_{\text{mice/cells}}=2-4/6-7$ ,  
245 saline (black) versus NP-MORwd (red),  $t_{11}=0.575$ ,  $P=0.577$ ). Sal, saline; Mor,  
246 morphine; Nlx, naloxone; PAG, periaqueductal gray; DG, dentate gyrus; MHb,  
247 medial habenula; SNr, substantia nigra pars reticulata.

248







249 **Figure 2 Microglia and cytokine signaling in the LHb during MORwd.**

250 (a) Representative max-projection of confocal acquisition of the LHb,  
251 depicting Iba1-positive microglia (left). Representative max-projection of  
252 microglia obtained in the <sup>Med</sup>LHb of mice in saline and NP-MORwd (top right).  
253 Representative 3D reconstruction of Iba1 positive microglia, containing CD68-  
254 positive structures, acquired in the <sup>Med</sup>LHb of mice in saline and NP-MORwd  
255 (bottom right). (b) Analysis of relative intensity of Iba1 microglia  
256 immunoreactivity in <sup>Med</sup>LHb in the different experimental groups (Saline (black)  
257  $n_{\text{mice/cells}}=4/366$ , NP-MORwd (red)  $n_{\text{mice/cells}}=4/328$ ,  $t_{692}=3.305$ ,  $***P=0.001$ ). (c,  
258 d) Quantitative analysis of microglial cell volume (based on Iba1-  
259 immunoreactivity) and volume of CD68-positive structures. Values are  
260 normalized to Saline control (Saline (black)  $n_{\text{mice/cells}}=4/89$ , NP-MORwd (red)  
261  $n_{\text{mice/cells}}=4/83$ ; Iba1 volume,  $t_{170}=3.05$ ,  $**P=0.003$ ; CD68/Iba1 volume,  
262  $t_{170}=2.65$ ,  $**P=0.008$ ). (e) TNF $\alpha$  (cyan) and DAPI (magenta) immunostaining

263 and normalized TNF $\alpha$  optical density in the LHb ( $n_{\text{mice/samples}}=7-8/3-6$ , saline  
264 (black) versus NP-MORwd (red),  $t_{13}=2.991$ ,  $*P=0.0104$ ).

265

266 **Figure 3 TNF $\alpha$  signaling modulates habenular AMPAR-mediated**  
267 **transmission.**

268 (a) AMPAR:NMDAR ratios  from naloxone-injected saline mice  
269 in <sup>Lat</sup>LHb without (-) or with (+) exogenous TNF $\alpha$  ( $n_{\text{mice/cells}}=2/7-9$ ,  
270 saline+naloxone (-) TNF  vs saline+naloxone (+)TNF $\alpha$   lighter  
271 gray :  $t_{14}=0.37$ ,  $P=0.717$ ). (b) AMPAR:NMDAR ratios without (-) or with (+)  
272 exogenous TNF $\alpha$   from naloxone-injected saline (black and  
273 gray) and morphine (red and pink) mice in <sup>Med</sup>LHb ( $n_{\text{mice/cells}}=3-5/10-15$ ,  
274 interaction factor  $F_{(1, 42)}=4.90$  two-way ANOVA,  $*P=0.039$ ). (c) <sup>Med</sup>LHb  
275 AMPAR:NMDAR ratios from saline or MPLA-treated, instead of naloxone,  
276 mice ( $n_{\text{mice/cells}}=3-4/10-11$ , morphine/saline (open red) versus morphine/MPLA  
277 (pink),  $t_{19}=3.070$ ,  $**P=0.006$ ). (d) MPLA (1 g/ml) effect on AMPAR-EPSCs in  
278 <sup>Med</sup>LHb (baseline (1) vs post-MPLA (2)) (MOR (open red),  $n_{\text{mice/cells}}=4/11$ ,  
279  $t_{10}=5.168$ ,  $***P=0.0004$ ; NP-MORwd (filled red),  $n_{\text{mice/cells}}=3/10$  cells,  $t_9=0.779$ ,  
280  $P=0.456$ ; MOR versus NP-MORwd,  $t_{19}=2.419$ ,  $*P=0.026$ ).

281

282 **Figure 4 TNFR1 is required for MORwd-driven synaptic and behavioural**  
283 **adaptations.**

284 (a) Experimental protocol using TNF-R1<sup>fl/fl</sup> mice. (b) Image and (c)  
285 quantification of AAV-Cre-infected LHb neurons (magenta) and total LHb  
286 neurons (cyan) from three mice (M1, M2 and M3). (d) AMPAR:NMDAR ratios  
287 from <sup>Med</sup>LHb of: AAV<sub>Control</sub>-TNF-R1<sup>fl/fl</sup> (saline (gray) versus NP-MORwd (red))  
288 or AAV<sub>Cre</sub>-TNF-R1<sup>fl/fl</sup> (saline (open gray) versus NP-MORwd (open pink))  
289 ( $n_{\text{mice/cells}}=7-8/9-14$ , interaction factor  $F_{(1,44)}=4.887$  two-way ANOVA,  
290  $*P=0.032$ ). (e) Tracking plots of social preference test (SPT) in C57/BI6 mice.  
291 Box/scatter plots showing social preference score (saline (black) versus NP-  
292 MORwd (red),  $n_{\text{mice}}=22$  /group,  $t_{42}=2.559$ ,  $*P=0.014$ ). Animals indicated with  
293 pink filled circles were used for AMPAR:NMDAR ratio recordings shown in (f).  
294 (f) Correlation of AMPAR:NMDAR ratios and social preference score  
295 ( $n_{\text{mice/cells}}=4/12$  ; Pearson's  $r^2=0.954$ ;  $*P=0.023$ ). (g) Tracking and box/scatter

296 plots of SPT in TNF-R1<sup>fl/fl</sup> mice (AAV<sub>Control</sub>: saline (black), NP-MORwd (red),  
297 n<sub>mice</sub>=20/23 mice; AAV<sub>Cre</sub>: saline (open gray), NP-MORwd (open pink),  
298 n<sub>mice</sub>=13 mice/group, interaction factor  $F_{(1, 65)} = 7.20$  two-way ANOVA,  
299 \*\*P=0.009). S, social stimulus; O, object.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344 **Methods**

345 **Animals and morphine treatments.** C57Bl/6J wild-type (male) and 129-  
346 Tnfrsf1atm3Gkl (male and female, referred as TNF-R1<sup>fl/fl</sup>) mice of 4–10 weeks  
347 were group-housed (three to five per cage) on a 12:12 h light cycle (lights on  
348 at 7 a.m.) with food and water ad libitum. All procedures aimed to fulfill the 3R  
349 criterion and were approved by the Veterinary Offices of Vaud (Switzerland;  
350 License VD3172). Part of the current study was carried out in the Institut du  
351 Fer a Moulin, Paris and experiments were in accordance with the guidelines  
352 of the French Agriculture and Forestry Ministry. Morphine withdrawal was  
353 either precipitated with naloxone or was induced naturally. For naloxone-  
354 precipitated morphine withdrawal, mice were subjected to six-day  
355 intraperitoneal (i.p.) morphine (20mg/kg, Cantonal Hospital of Lausanne,  
356 CHUV, Switzerland) or saline injections (saline and morphine-treated animals  
357 were housed together). On day 6, the last morphine/saline injection was given  
358 in a separate cage, thirty minutes after which animals received an i.p. injection  
359 of naloxone hydrochloride (2mg/kg, Abcam). Morphine withdrawal  
360 dependence symptoms were allowed to develop in the following thirty  
361 minutes, after what mice were either sacrificed for *ex vivo* electrophysiological  
362 recordings or were subjected to behavioral tests.

363

364 For spontaneous withdrawal, mice were treated with morphine or saline for 6  
365 days and were sacrificed for recordings 10-13, 20 or 30 days after the last  
366 injection. For recordings in morphine-treated animals not in withdrawal, mice  
367 were sacrificed one hour after the last morphine injection on day 6. To assess  
368 TNF $\alpha$  involvement in morphine withdrawal plasticity, part of the animals were  
369 subjected to an i.p. injection of MPLA (Monophosphoryl Lipid A, 10  $\mu$ g, a Toll-  
370 like receptor 4 activator dissolved in DMSO and saline) or saline (containing  
371 the same amount of DMSO as control) instead of naloxone thirty minutes after  
372 the last morphine injection on day 6. Another portion of the animals received  
373 an i.p. injection of a dominant negative peptide blocking the soluble form of  
374 TNF $\alpha$  (XENP1595, 30mg/kg, Xencor, US) one hour prior the last morphine  
375 or saline injection on day 6. Thirty minutes after the morphine/saline injection  
376 these animals received naloxone and were sacrificed for recordings as  
377 described above.

378

379 **Surgery.** Animals of at least 4 weeks were anesthetized with ketamine (150  
380 mg/kg)/xylazine (100 mg/kg) i.p. (Veterinary office University of Lausanne)  
381 and were placed on a stereotactic frame (Kopf, Germany). Bilateral injections  
382 of 200-400 nl volume were performed through a glass needle, at a rate of  
383 approximately 100 nl min<sup>-1</sup>. The injection pipette was withdrawn from the  
384 brain 10 min after the infusion. Retrobeads (Lumafluor) were infused into the  
385 dorsal raphe nucleus (A-P:-3.5; M-L:0;D-V:-3.8 mm) or ventral tegmental area  
386 (A-P:-2.4; M-L:±0.65;D-V:-4.9 mm) of C57Bl6 mice. 129-Tnfrsf1atm3Gki mice  
387 were injected with either rAAV2-hSyn-eGFP or rAAV2-hSyn or CMV-Cre-  
388 eGFP into the LHb (A-P:-1.35; M-L: ±0.45;D-V:-3.00 mm). In another set of  
389 experiments C57Bl6 mice were injected with a herpes simplex virus derived  
390 hEF1α-cre vector (MGA Gene delivery technology core, Cambridge, MA,  
391 USA) in the raphe nucleus and with rAAV-DJ-EF1α-Flex-hM4D(Gi)-mCherry  
392 (Gene vector and virus core, Stanford medicine, CA, USA) in the LHb.  
393 Animals were allowed to recover for about 5-7 days after retrobeads injections  
394 or 5 weeks after viral infusion before being submitted to morphine/saline  
395 treatment. The injection sites were carefully examined for all electrophysiology  
396 experiments and only animals with correct injections were used for  
397 recordings. Similarly, for behavioral studies only animals with correct injection  
398 sites were included in the analysis. Brain slices from mice injected with  
399 retrobeads or viruses were directly examined under an epifluorescence  
400 microscope.

401

402 **Ex-vivo electrophysiology.** Animals of 5 weeks were anesthetized with  
403 ketamine/ xylazine; 150 mg/kg/100 mg/kg i.p. for preparation of LHb-  
404 containing brain slices. Slicing was done in bubbled ice- cold 95% O<sub>2</sub>/5%  
405 CO<sub>2</sub>-equilibrated solution containing (in mM): choline chloride 110; glucose  
406 25; NaHCO<sub>3</sub> 25; MgCl<sub>2</sub> 7; ascorbic acid 11.6; sodium pyruvate 3.1; KCl 2.5;  
407 NaH<sub>2</sub>PO<sub>4</sub> 1.25; CaCl<sub>2</sub> 0.5. Coronal slices (250 μm) were prepared and  
408 transferred for 10 min to warmed solution (34 °C) of identical composition,  
409 before they were stored at ~22 °C in 95% O<sub>2</sub>/5% CO<sub>2</sub>-equilibrated artificial  
410 cerebrospinal fluid (ACSF) containing (in mM): NaCl 124; NaHCO<sub>3</sub> 26.2;  
411 glucose 11; KCl 2.5; CaCl<sub>2</sub> 2.5; MgCl<sub>2</sub> 1.3; NaH<sub>2</sub>PO<sub>4</sub> 1. Recordings (flow

412 rate of 2.5 ml/min) were made under an Olympus-BX51 microscope  
413 (Olympus) at 32 °C. Patch-clamp experiments were performed using  
414 borosilicate glass pipettes (2.7–4 M $\Omega$ ; Phymep, France). Currents were  
415 amplified, filtered at 5 kHz and digitized at 20 kHz (Multiclamp 200B;  
416 Molecular Devices, USA). Data were acquired using Igor Pro with NIDAQ  
417 tools (Wavemetrics, USA). Access resistance was monitored by a step of –4  
418 mV (0.1 Hz). Experiments were discarded if the access resistance increased  
419 more than 20%. All recordings were made in voltage-clamp configuration.  
420 Spontaneous EPSCs were recorded either in the lateral or in the medial  
421 territory of the LHb at –60 mV in presence of picrotoxin (100  $\mu$ M, Abcam) and  
422 APV (50  $\mu$ M, Abcam). The internal solution contained (in mM): CsCl 130;  
423 NaCl 4; MgCl<sub>2</sub> 2; EGTA 1.1; HEPES 5; Na<sub>2</sub>ATP 2; sodium creatine-  
424 phosphate 5; Na<sub>3</sub>GTP 0.6; spermine 0.1. The liquid junction potential was –3  
425 mV and was not compensated. For AMPAR:NMDAR ratios EPSCs were  
426 evoked through glass electrodes placed ~200  $\mu$ m from the recording site  
427 using AMPI ISO-Flex stimulator. A mixture of AMPA and NMDA currents were  
428 evoked at +40 mV (in presence of picrotoxin). The two components were  
429 pharmacologically isolated by adding APV in the recording solution and by  
430 subsequent identification of the individual currents via digital subtraction. For  
431 glutamate uncaging experiments MNI-glutamate (4-methoxy-7-nitroindoliny-  
432 caged L-glutamate 500 $\mu$ M, Tocris) was added to the recording solution.  
433 Uncaging was obtained via a single-path photolysis head (Prairie  
434 Technologies) connected to a solid-state laser (Rapp Optoelectronics,  
435 Germany; 405 nm, duration 1 ms, diameter 3–5 $\mu$ m, 250–300 $\mu$ m from soma).  
436 AMPAR:NMDAR ratios in uncaging experiments were calculated as follows:  
437 AMPA-EPSC at –60 mV/NMDA-EPSCs at +40 mV and the individual  
438 components were identified as previously described, using the late  
439 component of the EPSC at 30 ms after the onset (Maroteaux and Mameli,  
440 2012). Rectification index was computed by recording AMPA-EPSC at –70  
441 and +40 mV and was calculated as follows: (AMPA-EPSC at –70/AMPA-  
442 EPSC at +40)/1.75. To assess presynaptic release properties, trains of  
443 AMPAR-EPSCs were evoked using extracellular stimulating electrode (5  
444 pulses at 5Hz, 10Hz and 20Hz). The amplitudes of EPSCs trains were  
445 normalized to the amplitude of the first pulse. When indicated recordings were

446 performed from retrogradely labeled and fluorescently identified LHb neurons.  
447 Some experiments were performed in LHb-containing slices incubated for  
448 minimum one hour with exogenous TNF $\alpha$  (100ng/ml). To test the effect of  
449 MPLA on AMPAR transmission, neurons were patched either in the lateral or  
450 the medial territory of the LHb and EPSCs were evoked with extracellular  
451 stimulation. Following a ten-minute baseline, MPLA (1 $\mu$ g/ml) was added to  
452 the recording solution and EPSCs were recorded minimum 40 minutes after.  
453 Some experiments were performed in presence of the TNF $\alpha$ -dominant  
454 negative peptide (1 $\mu$ g/ml; XENP1595, Xencor, US) in the recording  
455 solution.

456

#### 457 **Non stationary fluctuation analysis.**

458 A peak-scaled nonstationary fluctuation analysis (NSFA) was performed on  
459 sEPSCs (# of events, 70–250) (Synaptosoft, USA). sEPSCs were selected  
460 by: fast rise time alignment, stable baseline holding current, and the absence  
461 of spurious fluctuations during the sEPSCs decay. The variance–amplitude  
462 relationship of sEPSC decay was plotted and fitted with the equation  
463  $\sigma^2 = iI - I^2/N + \sigma_b^2$  (where  $i$  is the mean single-channel AMPA current,  $I$  is the  
464 mean current,  $N$  is the number of channels activated at the peak,  $N = \text{mean}$   
465  $\text{amplitude}/i$ ; and  $\sigma^2$  is the baseline variance).  $i$  was estimated as the slope of  
466 the linear fit of the first portion of the parabola of the fitted sEPSC decay. The  
467 goodness-of-fit was assessed with a least-squares algorithm. The unitary  
468 current was converted in conductance based on the reversal potential of  
469 evoked EPSCs (0 mV) and the holding potential (–60 mV). Conductance and  
470 average EPSC amplitude, mean rise time, mean decay time, access  
471 resistance, or background noise variance had no correlation ( $p > 0.4$ )  
472 (Maroteaux and Mameli, 2012).

473

474 **Histology and immunofluorescence.** Mice were injected daily with  
475 saline/morphine (20mg/kg, i.p.) for 6 days. Some mice were left to develop  
476 spontaneous withdrawal, while others received naloxone (2mg/kg, i.p.)  
477 injection 30 min after the last saline/morphine injection on day 6. After 10-13  
478 days of spontaneous withdrawal or 30 min after naloxone injection mice were

479 anesthetized and perfused with cold 4% paraformaldehyde (PFA) in PBS  
480 (phosphate-buffered saline). The brains were extracted, post-fixed in 4% PFA  
481 in PBS, and incubated in 30% sucrose in PBS until they sank. 30  $\mu$ m slices  
482 were cut at the cryostat, and stored in PBS containing 0.02% NaN<sub>3</sub> for future  
483 analysis. For the immunofluorescence, the slices were incubated 2h in  
484 blocking buffer (5% NGS, 0.3% Triton-X in PBS) and then 24h at 4°C with the  
485 primary antibody solution (mouse anti-TNF $\alpha$  antibody, ab1793, Abcam, 1:100  
486 in blocking buffer). After extensive rinses, the secondary antibody was applied  
487 (goat anti-mouse IgG-conjugated Alexa 488, Invitrogen, 1:400 in blocking  
488 buffer, 24h at 4°C). The slices were then incubated in a 1:400 DAPI solution in  
489 PBS, extensively rinsed, mounted on glass slides with Pro-Long Gold Antifade  
490 Reagent (Invitrogen) and coverslipped. Images were acquired with an  
491 epifluorescent microscope with a 20x objective (AxioVision, Zeiss) using the  
492 same parameters for all the samples. The images were analyzed and  
493 processed with ImageJ software. Optical density was measured on the whole  
494 LHb area, and normalized on the neighboring thalamus [LHb-  
495 Thal/(LHb+Thal)]. 3-6 slices distributed in the rostrocaudal axis were analyzed  
496 per each animal (8 morphine, 7 saline).

497

#### 498 **Microglia analysis**

499 Mice were anesthetized and perfused with cold 4% paraformaldehyde (PFA)  
500 in PBS (phosphate-buffered saline). The brains were extracted, post-fixed in  
501 4% PFA in PBS, and incubated in 30% sucrose in PBS until they sank. 30  $\mu$ m  
502 slices were cut at the cryostat, and stored in PBS containing 0.02% NaN<sub>3</sub> for  
503 future analysis. Brain sections were permeabilized at room temperature (RT)  
504 in 0.5% Triton X-100 (Sigma) for 1 hr RT, followed by 1 hr RT blocking in 2%  
505 BSA 0.5% Triton X-100 and overnight incubation with primary antibody (Iba1  
506 1:1000, Wako Chemicals, Cat. No. 019-19741 and CD68 1:400, Bio-Rad Cat.  
507 No. MCA1957) at 4°C. Upon washing, sections were incubated 2 hr RT with  
508 Alexa-fluorophore-conjugated secondary antibodies (Invitrogen), and  
509 counterstained with DAPI (Invitrogen).

510 Confocal microscopy was performed with a TCS-SP5 (Leica) Laser Scanning  
511 System, by using a 20X dry objective and images were processed and  
512 analyzed by Fiji Software or Imaris Software (Bitplane, Switzerland), as



513 appropriate. Imaris was used for 3D rendering of confocal images for  
514 quantification of volumes.  
515 For density analysis, for each acquisition, the DAPI channel was max-  
516 projected and the medial and lateral portions of the lateral habenula were  
517 manually drawn as region of interest. Then, stacks ranging from 15 to 20 $\mu$ m in  
518 thickness, with z-step size of 1 $\mu$ m, were processed as follows: Iba1 and DAPI  
519 channels were thresholded in Fiji and multiplied to each other for each stack,  
520 with the image calculator function. The resulting thresholded stack was max-  
521 projected and the microglia nuclei were counted with Analyze Particle  
522 function.  
523 For cell soma size and Iba1 intensity, each acquisition was max-projected and  
524 the contour of cell somata in the medial portion of the lateral habenula were  
525 manually drawn based on the Iba1 immunoreactivity, and analyzed per size in  
526  $\mu$ m<sup>2</sup> and intensity.  
527 3D imaging analysis was performed by Imaris applying recorded algorithms  
528 (fixed thresholds for signal intensity) to all the images of the same experiment,  
529 in order to produce unbiased signal quantification. In each experiment, one  
530 brain slice per animal (n=4) per each group was acquired. The microglial cell  
531 volume and the volume of phagocytic structures were reconstructed based on  
532 the absolute intensity of Iba1 and CD68 signals, respectively. The volume of  
533 CD68 was then normalized for the Iba1 volume, to take in account the cell  
534 size.

535

### 536 **Behavior.**

537 **Social preference test.** A three-chambered social preference test was used,  
538 consisting in a rectangular Plexiglas arena (60 × 40 × 22 cm) (Ugo Basile,  
539 Varese, Italy) divided into three chambers. The walls of the center chamber  
540 had doors to allow free access to all compartments. The luminosity was  
541 around 10 lux. Thirty minutes after naloxone injection each mouse was placed  
542 in the arena for a habituation period of 10 min and was allowed to freely  
543 explore the whole empty arena. The social preference test was performed  
544 immediately after the end of the habituation: two enclosures with vertical bars  
545 were placed in the middle of the two lateral compartments, while the central  
546 chamber remained empty. One enclosure was empty (serving as an

547 inanimate object) whereas the other contained a social stimulus (unfamiliar  
548 juvenile mouse  $25 \pm 1$  days old). The enclosures allowed visual, auditory,  
549 olfactory and tactile contact between the experimental mice and the social  
550 stimuli mice. The juvenile mice in the enclosures were habituated to the  
551 apparatus and the enclosures for 3 days before the experiment and each one  
552 of them served as a social stimulus for no more than 2 experimental mice (at  
553 least 6 weeks old). The test lasted 10 minutes where experimental mice were  
554 allowed to freely explore the apparatus and the enclosures. The position of  
555 the empty and juvenile-containing enclosures alternated and was  
556 counterbalanced for each trial to avoid any bias effects. Every session was  
557 video-tracked and recorded using Ethovision XT (Noldus, Wageningen, the  
558 Netherlands) or AnyMaze (Stoelting, Ireland), which provided an automated  
559 recording of the entries and time spent in the compartments, the distance  
560 moved and the velocity. The time spent in each chamber was assessed and  
561 then used to determine the preference score for the social compartment as  
562 compared to the object compartment (social/(social + object)). The arena was  
563 cleaned with 1% acetic acid solution and dried between trials.

564

565 **Analysis and statistics.** Animals were randomly assigned to experimental  
566 groups. Compiled data are always reported and represented as whisker box  
567 plots (whisker top/bottom represent 90/10<sup>th</sup> percentile, box top/bottom  
568 represent 75/25<sup>th</sup> percentile and median) or mean  $\pm$  SEM, with single data  
569 points plotted (single cell for electrophysiology and single animal for  
570 behavioral experiments). Animals or data points were not excluded and  
571 normality test was applied. When applicable, statistical tests were paired or  
572 unpaired t-test and one-way or two-way ANOVA. Significance for correlations  
573 was obtained applying Pearson's estimates. Testing was always performed  
574 two-tailed with  $\alpha = 0.05$ .

575

576

577

578

579

580

581 **References**

- 582 1. Goeldner, C. *et al.* Impaired emotional-like behavior and serotonergic  
583 function during protracted abstinence from chronic morphine. *Biol*  
584 *Psychiatry* **69**, 236-244 (2011).
- 585 2. Lutz, P. E. *et al.* Distinct mu, delta, and kappa opioid receptor  
586 mechanisms underlie low sociability and depressive-like behaviors  
587 during heroin abstinence. *Neuropsychopharmacology* **39**, 2694-2705  
588 (2014).
- 589 3. Meye, F. J., Trusel, M., Soiza-Reilly, M. & Mameli, M. Neural circuit  
590 adaptations during drug withdrawal - Spotlight on the lateral habenula.  
591 *Pharmacol Biochem Behav* **162**, 87-93 (2017).
- 592 4. Margolis, E. B. & Fields, H. L. Mu Opioid Receptor Actions in the Lateral  
593 Habenula. *PLoS One* **11**, e0159097 (2016).
- 594 5. Wang, J. *et al.* Inhibition of the lateral habenular CaMK $\alpha$  abolishes  
595 naloxone-precipitated conditioned place aversion in morphine-dependent  
596 mice. *Neurosci Lett* **653**, 64-70 (2017).
- 597 6. Valentinova, K. & Mameli, M. mGluR-LTD at Excitatory and Inhibitory  
598 Synapses in the Lateral Habenula Tunes Neuronal Output. *Cell Rep* **16**,  
599 2298-2307 (2016).
- 600 7. Pollak Dorocic, I. *et al.* A whole-brain atlas of inputs to serotonergic  
601 neurons of the dorsal and median raphe nuclei. *Neuron* **83**, 663-678  
602 (2014).
- 603 8. Hao, S. *et al.* The role of TNF $\alpha$  in the periaqueductal gray during  
604 naloxone-precipitated morphine withdrawal in rats.  
605 *Neuropsychopharmacology* **36**, 664-676 (2011).
- 606 9. Lewitus, G. M. *et al.* Microglial TNF- $\alpha$  Suppresses Cocaine-Induced  
607 Plasticity and Behavioral Sensitization. *Neuron* **90**, 483-491 (2016).
- 608 10. Campbell, L. A., Avdoshina, V., Rozzi, S. & Mochetti, I. CCL5 and  
609 cytokine expression in the rat brain: differential modulation by chronic  
610 morphine and morphine withdrawal. *Brain Behav Immun* **34**, 130-140  
611 (2013).
- 612 11. Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. Physiology  
613 of microglia. *Physiol Rev* **91**, 461-553 (2011).
- 614 12. Michaud, M. *et al.* Proinflammatory cytokines, aging, and age-related  
615 diseases. *J Am Med Dir Assoc* **14**, 877-882 (2013).
- 616 13. Probert, L. TNF and its receptors in the CNS: The essential, the  
617 desirable and the deleterious effects. *Neuroscience* **302**, 2-22 (2015).
- 618 14. Lecca, S. *et al.* Rescue of GABAB and GIRK function in the lateral  
619 habenula by protein phosphatase 2A inhibition ameliorates depression-  
620 like phenotypes in mice. *Nat Med* **22**, 254-261 (2016).
- 621 15. Meye, F. J. *et al.* Cocaine-evoked negative symptoms require AMPA  
622 receptor trafficking in the lateral habenula. *Nat Neurosci* **18**, 376-378  
623 (2015).
- 624 16. Benekareddy, M. *et al.* Identification of a Corticohabenular Circuit  
625 Regulating Socially Directed Behavior. *Biol Psychiatry* **83**, 607-617  
626 (2018).
- 627 17. Nie, X. *et al.* The Innate Immune Receptors TLR2/4 Mediate Repeated  
628 Social Defeat Stress-Induced Social Avoidance through Prefrontal  
629 Microglial Activation. *Neuron* **99**, 464-479.e7 (2018).
- 630 18. Patel, A., Siegel, A. & Zalcman, S. S. Lack of aggression and anxiolytic-

- 631 like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice.  
632 *Brain Behav Immun* **24**, 1276-1280 (2010).
- 633 19. Zhan, Y. *et al.* Deficient neuron-microglia signaling results in impaired  
634 functional brain connectivity and social behavior. *Nat Neurosci* **17**, 400-  
635 406 (2014).
- 636 20. Hutchinson, M. R. *et al.* Proinflammatory cytokines oppose opioid-  
637 induced acute and chronic analgesia. *Brain Behav Immun* **22**, 1178-1189  
638 (2008).
- 639 21. He, P., Liu, Q., Wu, J. & Shen, Y. Genetic deletion of TNF receptor  
640 suppresses excitatory synaptic transmission via reducing AMPA receptor  
641 synaptic localization in cortical neurons. *FASEB J* **26**, 334-345 (2012).
- 642 22. Stellwagen, D., Beattie, E. C., Seo, J. Y. & Malenka, R. C. Differential  
643 regulation of AMPA receptor and GABA receptor trafficking by tumor  
644 necrosis factor-alpha. *J Neurosci* **25**, 3219-3228 (2005).
- 645 23. Lewitus, G. M., Pribiag, H., Duseja, R., St-Hilaire, M. & Stellwagen, D. An  
646 adaptive role of TNF $\alpha$  in the regulation of striatal synapses. *J Neurosci*  
647 **34**, 6146-6155 (2014).
- 648 24. Cui, Y. *et al.* Astroglial Kir4.1 in the lateral habenula drives neuronal  
649 bursts in depression. *Nature* **554**, 323-327 (2018).
- 650 25. van Kerkhof, L. W., Damsteegt, R., Trezza, V., Voorn, P. &  
651 Vanderschuren, L. J. Functional integrity of the habenula is necessary for  
652 social play behaviour in rats. *Eur J Neurosci* **38**, 3465-3475 (2013).
- 653 26. Kane, M. J. *et al.* Mice genetically depleted of brain serotonin display  
654 social impairments, communication deficits and repetitive behaviors:  
655 possible relevance to autism. *PLoS One* **7**, e48975 (2012).
- 656 27. Lecca, S. *et al.* Aversive stimuli drive hypothalamus-to-habenula  
657 excitation to promote escape behavior. *Elife* **6**, (2017).
- 658 28. Matthews, G. A. *et al.* Dorsal Raphe Dopamine Neurons Represent the  
659 Experience of Social Isolation. *Cell* **164**, 617-631 (2016).
- 660 29. Wang, R. Y. & Aghajanian, G. K. Physiological evidence for habenula as  
661 major link between forebrain and midbrain raphe. *Science* **197**, 89-91  
662 (1977).

663  
664

## 665 **Acknowledgements**

666 We thank F.J. Meye and the entire Mameli Laboratory for discussions and  
667 comments on the manuscript. This work was supported by funds from the  
668 Canton of Vaud, ERC StG Saliensy 335333, the SNSF (31003A) and The  
669 Novartis Foundation to M.M. We thank David Szymkowski (Xencor, US) for  
670 the donation of XENP1595, and Prof. Georg Kollias (Fleming, Vari, Greece)  
671 and Hiltrud Strubbe for the use and breeding of TNF-R1 mouse line.

672

## 673 **Author contributions**

674 K.V., A.T. and M.M. performed and analyzed *ex vivo* electrophysiological  
675 recordings. A.L.L and J.C. contributed to *ex-vivo* recordings. K.V and A.T.

676 performed the behavioral experiments. M.T. I.M. and L.M. performed  
677 molecular biology experiments. M.T., C.B. and S.T. provided support for  
678 behavioral experiments. A.M. and R.C.P. performed and analyzed the  
679 experiments related to microglia morphology. A.V. provided conceptual and  
680 experimental input related to the TNF $\alpha$  signaling, including use of TNFR1<sup>fl/fl</sup>  
681 mice and their breeding. K.V. and M.M. conceptualized and designed the  
682 study and wrote the manuscript with the help of all authors.

683

684 **Competing financial interests**

685 The authors declare no competing financial interests.

686

687 **Statement on data availability**

688 The data sets generated during and/or analyzed during the current study are  
689 available from the corresponding author on reasonable request.

690

691

692

693

694

695

696




Fig 1., Valentinova, Tchenio et al.




Fig 2., Valentinova, Tchenio et al.




Fig 3., Valentinova, Tchenio et al.






Fig 4., Valentinova, Tchenio et al.